Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESK-001 Multiple Dose Study in Healthy Participants
NCT05431634Phase 1Completed
- Sponsor
- Alumis Inc.
- Start
- May 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in plaque psoriasis and systemic lupus erythematosus (SLE) comparing Experimental Drug ESK-001 with Placebo (2 arms). Primary endpoints: Incidence of Adverse Events (AEs) up to 14 days and Incidence of Serious Adverse Events (SAEs) up to 14 days. Started May 2022; status: completed.
02
Drugs
envudeucitinib
03
Conditions
plaque psoriasissystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05431634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431634.